Exacerbation of myasthenia gravis by alendronate

Kesikburun, Serdar; Güzelküçük, Ümüt; Alay, Semih; Yavuz, Ferdi; Tan, Arif Kenan

doi:10.1007/s00198-014-2768-4

Cited by 7 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In MG, the use of oral alendronate (70 mg/week) in a patient under GC treatment improved the LS BMD of 3.4% after 12 months without side effects (103). However, caution should be paid for possible exacerbation of MG symptoms, such as muscle weakness and extreme fatigue, after drug administration (104).…”

Section: Therapeutic Opportunitiesmentioning

confidence: 99%

Neuromuscular Diseases and Bone

et al. 2019

View full text Add to dashboard Cite

Neuromuscular diseases (NMDs) are inherited or acquired conditions affecting skeletal muscles, motor nerves, or neuromuscular junctions. Most of them are characterized by a progressive damage of muscle fibers with reduced muscle strength, disability, and poor health-related quality of life of affected patients. In this scenario, skeletal health is usually compromised as a consequence of modified bone–muscle cross-talk including biomechanical and bio-humoral issues, resulting in increased risk of bone fragility and fractures. In addition, NMD patients frequently face nutritional issues, including malnutrition due to feeding disorders and swallowing problems that might affect bone health. Moreover, in these patients, low levels of physical activity or immobility are common and might lead to overweight or obesity that can also interfere with bone strength features. Also, vitamin D deficiency could play a critical role both in the pathogenesis and in the clinical scenario of many NMDs, suggesting that its correction could be useful in maintaining or enhancing bone health, especially in the early phases of NMDs. Last but not least, specific disease-modifying drugs, available for some NMDs, are frequently burdened with adverse effects on bone tissue. For example, glucocorticoid therapy, standard of care for many muscular dystrophies, prolongs long-term survival in treated patients; nevertheless, high dose and/or chronic use of these drugs are a common cause of secondary osteoporosis. This review addresses the current state of knowledge about the factors that play a role in determining bone alterations reported in NMDs, how these factors can modify the biological pathways underlying bone health, and which are the available interventions to manage bone involvement in patients affected by NMDs. Considering the complexity of care of these patients, an interdisciplinary and multimodal management strategy based on both pharmacological and non-pharmacological interventions is recommended, particularly targeting musculoskeletal issues that are closely related to functional independence as well as social implications.

show abstract

Section: Therapeutic Opportunitiesmentioning

confidence: 99%

Neuromuscular Diseases and Bone

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, PRP has been shown to be safe with infection rates similar to that of controls. 351 However, these results need to be taken with caution as several, if not an equal number of studies have shown no significant pain relief, 352 quality of life and range of motion, 352,353 re-tear rates, [354][355][356] shoulder scores, 348,352,[354][355][356][357][358] or MRI analyses, 348,354,355,357,358 with the administration of PRPs. In addition, two meta-analyses on human trials for rotator cuff regeneration have shown no significance in terms of re-tear rates, strength regain and other clinical outcomes with PRP administration.…”

Section: Platelet-[rich Plasmamentioning

confidence: 99%

Regenerative Engineering of the Rotator Cuff of the Shoulder

Narayanan

Nair

Laurencin

2018

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Rotator cuff tears often heal poorly, leading to re-tears after repair. This is in part attributed to the low proliferative ability of the resident cells (tendon fibroblasts and tendon-stem cells) upon injury to the rotator cuff tissue and the low vascularity of the tendon insertion. In addition, surgical outcomes of current techniques used in clinical settings are often suboptimal, leading to the formation of neo-tissue with poor biomechanics and structural characteristics, which results in re-tears. This has prompted interest in a new approach, which we term as "Regenerative Engineering", for regenerating rotator cuff tendons. In the Regenerative Engineering paradigm, roles played by stem cells, scaffolds, growth factors/small molecules, the use of local physical forces, and morphogenesis interplayed with clinical surgery techniques may synchronously act, leading to synergistic effects and resulting in successful tissue regeneration. In this regard, various cell sources such as tendon fibroblasts and adult tissue-derived stem cells have been isolated, characterized, and investigated for regenerating rotator cuff tendons. Likewise, numerous scaffolds with varying architecture, geometry, and mechanical characteristics of biologic and synthetic origin have been developed. Furthermore, these scaffolds have been also fabricated with *

show abstract

“…These antiresorptive drugs, including bisphosphonates, strontium ranelate, and estrogen, are effective inhibitors of osteoclastic bone resorption [Brewer et al, ]. Unfortunately, long‐term treatment can induce serious side effects, such as acute influenza‐like illness, myasthenia gravis, and gastrointestinal cancer [Kesikburun et al, ; Jung et al, ]. Hence, new agents are required for reducing the risk of osteoporosis and osteoporotic fractures.…”

mentioning

confidence: 99%

Platycodin D Inhibits Osteoclastogenesis by Repressing the NFATc1 and MAPK Signaling Pathway

Choi

Han

Kim

et al. 2016

J of Cellular Biochemistry

View full text Add to dashboard Cite

Platycodon grandiflorum root-derived saponins (Changkil saponins, CKS) are reported to have many pharmacological activities. In our latest research, CKS was proven to have a significant osteogenic effect. However, the detail molecular mechanism of CKS on osteoclastic differentiation has not been fully investigated. Administration of CKS considerably reduced OVX-induced bone loss, and ameliorated the reduction in plasma levels of alkaline phosphatase, calcium, and phosphorus observed in OVX mice. CKS also repressed the deterioration of bone trabecular microarchitecture. Interestingly, platycodin D, the most abundant and major pharmacological constituent of triterpenoid CKS, inhibited receptor activator of NF-κB ligand (RANKL)-induced activation of NF-κB, and ERK and p38 MAPK, ultimately repressing osteoclast differentiation. OVX-induced bone turnover was attenuated by CKS, possibly via repression of osteoclast differentiation by platycodin D, the active component of CKS. Platycodin D can be regarded as an antiosteoporotic candidate for treatment of osteoporosis diseases. J. Cell. Biochem. 118: 860-868, 2017. © 2016 Wiley Periodicals, Inc.

show abstract

Exacerbation of myasthenia gravis by alendronate

Cited by 7 publications

References 5 publications

Neuromuscular Diseases and Bone

Neuromuscular Diseases and Bone

Regenerative Engineering of the Rotator Cuff of the Shoulder

Platycodin D Inhibits Osteoclastogenesis by Repressing the NFATc1 and MAPK Signaling Pathway

Contact Info

Product

Resources

About